Fig. 4.

Effect of intrinsic factors on the pharmacokinetics of apixaban [4]. *Subjects with end-stage renal disease (ESRD) treated with intermittent hemodialysis; reported pharmacokinetic (PK) findings are following a single dose of apixaban post-hemodialysis. ^†Creatinine clearance (CrCl) > 80 mL/min. ^‡Severe, moderate, mild, and normal reflect CrCl of 15 mL/min, 40 mL/min, 65 mL/min, and 100 mL/min based on regression analyses. AUC area under the plasma concentration–time curve, CI confidence interval, C_max maximum plasma concentration. Reproduced with permission from Eliquis (apixaban) US prescribing information